Alzheimer's Disease

all catalysts(0)

nothing on the calendar yet

News(10)

• Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
  Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
  fiercebiotech · 6d ago
• Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
  Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
  biopharma_dive · 1mo ago
• Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test
  Roche and Eli Lilly have won FDA clearance for their latest Alzheimer’s disease diagnostic.
  fiercebiotech · 1mo ago
• FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
  Lantheus, which recently agreed to an $8 billion takeover by fellow radiopharma Curium, garnered FDA clearance for its Alzheimer’s PET imaging agent Tauklarify.
  fiercebiotech · 1mo ago
• MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
  Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
  fiercebiotech · 1mo ago
• CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
  CytoDyn's leronlimab may have struggled to secure approval as an HIV treatment, but research in infant primates has offered fresh hope for the CCR5-targeting antibody's ability to treat the virus.
  fiercebiotech · 1mo ago
• Chutes & Ladders—BioNTech brings in Sobi CEO
  After a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…
  fiercebiotech · 1mo ago
• MapLight dives despite positive data for schizophrenia drug
  Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
  biopharma_dive · 2mo ago
• Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better
  LONDON — Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet that it could slow dementia. But the results wer…
  endpoints · 2mo ago
• Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
  The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
  biopharma_dive · 2mo ago